期刊
PHARMACEUTICS
卷 13, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics13040454
关键词
rheumatoid arthritis; drug delivery nanosystems; liposomes; passive targeting; active targeting
资金
- PT national funds from Fundacao para a Ciencia e Tecnologia (FCT) through the grant FCT/MEC [UID/DTP/04138/2020, UIDP/04138/2020]
- ULisboa, grant FCT/MEC [UIDP/04378/2020, UIDB/04378/2020]
- FCT/MCTES [UIDB/50006/2020]
- European Union (FEDER funds) [COMPETE POCI-01-0145-FEDER-029253]
- Phospholipid Research Center [LCO-2017-052/1-1]
- FCT i3DU PhD program [PD/BD/135,264/2017]
Rheumatoid arthritis is an autoimmune disease with available therapies, but there is a need for more effective treatments. Drug delivery systems like liposomes play a crucial role in treatment, but obstacles to successful clinical translation need to be addressed.
Rheumatoid arthritis (RA) is an autoimmune disease that affects the joints and results in reduced patient quality of life due to its chronic nature and several comorbidities. RA is also associated with a high socioeconomic burden. Currently, several available therapies minimize symptoms and prevent disease progression. However, more effective treatments are needed due to current therapies' severe side-effects, especially under long-term use. Drug delivery systems have demonstrated their clinical importance-with several nanocarriers present in the market-due to their capacity to improve therapeutic drug index, for instance, by enabling passive or active targeting. The first to achieve market authorization were liposomes that still represent a considerable part of approved delivery systems. In this manuscript, we review the role of liposomes in RA treatment, address preclinical studies and clinical trials, and discuss factors that could hamper a successful clinical translation. We also suggest some alterations that could potentially improve their progression to the market.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据